Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Within these divisions, the company provides a comprehensive portfolio of solutions addressing various gastrointestinal and pulmonary ailments, as well as urological and pelvic health concerns. This extends to advanced implantable devices for managing cardiac rhythm disorders, such as cardioverter-defibrillators, cardiac resynchronization therapy devices, and pacemakers, complemented by remote patient management systems. Furthermore, Boston Scientific offers sophisticated technologies for diagnosing and treating complex heart rate and rhythm irregularities. These encompass 3-D cardiac mapping and navigation tools, along with a suite of specialized catheters (including ablation, diagnostic, mapping, and intracardiac ultrasound types), delivery sheaths, and related accessories. Its offerings also extend to neurological conditions, providing spinal cord stimulator systems for chronic pain management, indirect decompression systems, and deep brain stimulation systems. In the realm of interventional cardiology, the company's innovations include drug-eluting coronary stent systems designed for treating coronary artery disease, products for percutaneous coronary interventions to combat atherosclerosis, and intravascular imaging catheters (such as ultrasound and fractional flow reserve devices) for assessing coronary arteries, heart chambers, and peripheral vessels. It also develops structural heart therapies. Beyond this, Boston Scientific supplies an array of stents, balloon catheters, wires, and atherectomy systems for the treatment of arterial diseases. For venous conditions, it provides thrombectomy and acoustic pulse thrombolysis systems, alongside wires and stents. Critically, the company also contributes to cancer treatment through peripheral embolization devices, radioactive microspheres, various ablation systems (including cryotherapy), and micro and drainage catheters. The organization was established in 1979 and maintains its corporate headquarters in Marlborough, Massachusetts.
前日終値
$42.73
+$0.69 · +1.64%
日中の時刻はETです。市場データは遅延する場合があります。
Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Within these divisions, the company provides a comprehensive portfolio of solutions addressing various gastrointestinal and pulmonary ailments, as well as urological and pelvic health concerns. This extends to advanced implantable devices for managing cardiac rhythm disorders, such as cardioverter-defibrillators, cardiac resynchronization therapy devices, and pacemakers, complemented by remote patient management systems. Furthermore, Boston Scientific offers sophisticated technologies for diagnosing and treating complex heart rate and rhythm irregularities. These encompass 3-D cardiac mapping and navigation tools, along with a suite of specialized catheters (including ablation, diagnostic, mapping, and intracardiac ultrasound types), delivery sheaths, and related accessories. Its offerings also extend to neurological conditions, providing spinal cord stimulator systems for chronic pain management, indirect decompression systems, and deep brain stimulation systems. In the realm of interventional cardiology, the company's innovations include drug-eluting coronary stent systems designed for treating coronary artery disease, products for percutaneous coronary interventions to combat atherosclerosis, and intravascular imaging catheters (such as ultrasound and fractional flow reserve devices) for assessing coronary arteries, heart chambers, and peripheral vessels. It also develops structural heart therapies. Beyond this, Boston Scientific supplies an array of stents, balloon catheters, wires, and atherectomy systems for the treatment of arterial diseases. For venous conditions, it provides thrombectomy and acoustic pulse thrombolysis systems, alongside wires and stents. Critically, the company also contributes to cancer treatment through peripheral embolization devices, radioactive microspheres, various ablation systems (including cryotherapy), and micro and drainage catheters. The organization was established in 1979 and maintains its corporate headquarters in Marlborough, Massachusetts.
日中レンジ
現在 $42.73
52週レンジ
現在 $42.73
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
買い
バリュエーション
95
大幅な割安
センチメント
77
強気
リスク
50
やや高いリスク
モメンタム
24
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Within these divisions, the company provides a comprehensive portfolio of solutions addressing various gastrointestinal and pulmonary ailments, as well as urological and pelvic health concerns. This extends to advanced implantable devices for managing cardiac rhythm disorders, such as cardioverter-defibrillators, cardiac resynchronization therapy devices, and pacemakers, complemented by remote patient management systems. Furthermore, Boston Scientific offers sophisticated technologies for diagnosing and treating complex heart rate and rhythm irregularities. These encompass 3-D cardiac mapping and navigation tools, along with a suite of specialized catheters (including ablation, diagnostic, mapping, and intracardiac ultrasound types), delivery sheaths, and related accessories. Its offerings also extend to neurological conditions, providing spinal cord stimulator systems for chronic pain management, indirect decompression systems, and deep brain stimulation systems. In the realm of interventional cardiology, the company's innovations include drug-eluting coronary stent systems designed for treating coronary artery disease, products for percutaneous coronary interventions to combat atherosclerosis, and intravascular imaging catheters (such as ultrasound and fractional flow reserve devices) for assessing coronary arteries, heart chambers, and peripheral vessels. It also develops structural heart therapies. Beyond this, Boston Scientific supplies an array of stents, balloon catheters, wires, and atherectomy systems for the treatment of arterial diseases. For venous conditions, it provides thrombectomy and acoustic pulse thrombolysis systems, alongside wires and stents. Critically, the company also contributes to cancer treatment through peripheral embolization devices, radioactive microspheres, various ablation systems (including cryotherapy), and micro and drainage catheters. The organization was established in 1979 and maintains its corporate headquarters in Marlborough, Massachusetts.
日中レンジ
現在 $42.73
52週レンジ
現在 $42.73
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標(USD) | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 200.74億 USD | 167.47億 USD | 142.4億 USD | 126.82億 USD | 118.88億 USD |
| 売上原価 | 62.21億 USD | 64.8億 USD | 54.09億 USD | 49.68億 USD | 44.27億 USD |
| 粗利益 | 138.53億 USD | 102.67億 USD | 88.31億 USD | 77.14億 USD | 74.61億 USD |
| 研究開発 | 20.52億 USD | 16.15億 USD | 14.14億 USD | 13.23億 USD | 12.04億 USD |
| 販売・一般管理 | 68.87億 USD | 59.84億 USD | 51.9億 USD | 45.2億 USD | 42.86億 USD |
| 営業費用 | 98.82億 USD | 76.32億 USD | 66.5億 USD | 58.9億 USD | 55.39億 USD |
| 受取利息 | — | 1.07億 USD | 2200万 USD | 1000万 USD | 400万 USD |
| 支払利息 | 3.49億 USD | 3.87億 USD | 2.72億 USD | 4.64億 USD | 3.49億 USD |
| 減価償却費と償却費 | 13.68億 USD | 12.69億 USD | 11.96億 USD | 11.36億 USD | 10.93億 USD |
| 営業利益 | 39.71億 USD | 26.35億 USD | 21.81億 USD | 18.24億 USD | 19.22億 USD |
| 純利益 | 28.86億 USD | 18.54億 USD | 15.93億 USD | 6.98億 USD | 10.4億 USD |
会社概要が更新されました 2026年10月12日.
この株式へのエクスポージャーを報告している上場投資信託です。
State Street SPDR S&P 500 ETF1557.T1175.08億0.09%129.43兆 JPY0.09%¥122,850+0.12%
Vanguard Morningstar Total Stock Market ETFVTI22.82億0.10%2.3兆 USD0.03%$381.94+0.63%
Vanguard S&P 500 ETFVOO19.07億0.11%1.8兆 USD0.03%$715.59+0.61%
iShares Core S&P 500 ETFIVV8.1億0.09%8964.4億 USD0.03%$781.97+0.60%
State Street SPDR S&P 500 ETFSPY7.42億0.09%8172億 USD0.09%$778.57+0.60%
Vanguard Morningstar Growth ETFVUG4.41億0.11%3846億 USD0.03%$91.97+0.72%
State Street Health Care Select Sector SPDR ETFXLV4.34億1.00%435.37億 USD0.08%$170.81+1.58%
Vanguard Morningstar Value ETFVTV3.43億0.13%2624億 USD0.03%$220.59+0.44%
State Street SPDR S&P 500 ETF1557.T
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard S&P 500 ETFVOO
iShares Core S&P 500 ETFIVV
State Street SPDR S&P 500 ETFSPY
Vanguard Morningstar Growth ETFVUG
State Street Health Care Select Sector SPDR ETFXLV
Vanguard Morningstar Value ETFVTVAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。